UK doctors, not courts, to decide on consent to puberty blockers in under-16s
The UK Court of Appeal overturned a ruling that restricted children’s access to drugs that pause puberty
17 September 2021 - 17:21
byRachel Savage
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
London — A British court on Friday overturned a ruling that restricted children’s access to puberty-blocking drugs — a new twist in a global debate over when someone can opt to medically transition genders.
It was the role of doctors, not courts, to decide if a child under 16 years was capable of consenting to drugs that pause puberty, the Court of Appeal for England and Wales said in its ruling.
The case was brought by 24-year-old Keira Bell, who says she regretted taking puberty blockers at 16 years and cross-sex hormones at 17 years, and an unnamed mother.
Their case — a first in Britain — inflamed divisions globally over how best to treat children who are transgender or questioning their gender.
The Tavistock and Portman NHS Foundation Trust, which runs England's only youth gender clinic, welcomed the decision.
“It affirms that it is for doctors, not judges, to decide on the capacity of under-16s to consent to medical treatment,” a spokesperson said in an emailed statement.
Bell’s lawyer, Paul Conrathe, said his clients would be seeking permission to appeal to the Supreme Court.
“We are both dismayed and surprised at the Court of Appeal’s decision, which appears to us the epitome of the triumph of legal formalism over justice and common sense,” he said by email.
“At a stroke the court’s decision removes a sensible, necessary and proportionate protection for vulnerable young children against the poorly evidenced treatment with lifelong, irreversible consequences.”
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
UK doctors, not courts, to decide on consent to puberty blockers in under-16s
The UK Court of Appeal overturned a ruling that restricted children’s access to drugs that pause puberty
London — A British court on Friday overturned a ruling that restricted children’s access to puberty-blocking drugs — a new twist in a global debate over when someone can opt to medically transition genders.
It was the role of doctors, not courts, to decide if a child under 16 years was capable of consenting to drugs that pause puberty, the Court of Appeal for England and Wales said in its ruling.
The case was brought by 24-year-old Keira Bell, who says she regretted taking puberty blockers at 16 years and cross-sex hormones at 17 years, and an unnamed mother.
Their case — a first in Britain — inflamed divisions globally over how best to treat children who are transgender or questioning their gender.
The Tavistock and Portman NHS Foundation Trust, which runs England's only youth gender clinic, welcomed the decision.
“It affirms that it is for doctors, not judges, to decide on the capacity of under-16s to consent to medical treatment,” a spokesperson said in an emailed statement.
Bell’s lawyer, Paul Conrathe, said his clients would be seeking permission to appeal to the Supreme Court.
“We are both dismayed and surprised at the Court of Appeal’s decision, which appears to us the epitome of the triumph of legal formalism over justice and common sense,” he said by email.
“At a stroke the court’s decision removes a sensible, necessary and proportionate protection for vulnerable young children against the poorly evidenced treatment with lifelong, irreversible consequences.”
Thomson Reuters Foundation
Transgender athlete debate rages at Games as weightlifting events go on
LGBTQ athletes better represented than ever at Olympics, but strife persists
LA TIMES: Transgender customers have same rights as others
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.